 Nid oedd ymlaen ni'n ei hwnnw amrades o'r beth hyn meantimeau y mae'n rhan o'r hwnnau yma, ond hefyd, a yn ddod ar ddweud hynny, ac nid oedd yn ddau ddweud hynny, a'r beth hynny yn ddim yn ei hwnnw fel package ardal yn dyfodol ac yn giliriau cyftyr hynny. Tofyn nid o'r beth, mae'n Police a'r beth hynny yn falch o'r yefnodol yrherwydd a'r gallwch o'r pobell, nid o'n ddweud hynny. I've got to say I'm not a financial advisor or I am a business teacher in my daily life, but I'm by no means an expert on the stock market. We'll get right into the information if you appreciate that direct approach then do leave the video a like it really helps out the channel as we try and grow to that 10,000 subscribers. That'd be absolutely fantastic if you could leave a like on the video so let's go right into the information. The stock we're talking about today is called Regulus Therapeutics and going into this mae'n roi rhoi'r hwnas hwn ymd transpethau. Mae'r hwn ymdangor iawn y gilydd ychwanegol. Yn ymdweud, yma, ffangard ganwch ymdman. Mae'n roi'r hwnwyr 2,6 miliwn y gilydd o yr unig, bydd yw'r hwn ymdangor iawn o'r hwn ymgaint. Ond, yma mor wneud yn ysgrifennu, mae'n ddod o'r wneud neud am bobl, oedd y gallwn hwn yw bêl yn ysgrifennu, ac mae'n gilydd o'r hwn ymdangor iawn byd yn cael o'r hwn. Mae acabodd anodd ar gyfer llMR. Mae hyn yn cael i anodd anodd anodd ti'r gennym. Felly mae anodd anodd anodd at first- abstract yn wedi anodd anodd a sut yn gwneud a mae canodd anodd dri. Efallai hi yw addastad â yna ar y cwyl fod ein anodd yn caelser. Yn cauецl-anodd, fe diwrnodd gyn 280 o ac meddwl â gyn insbesondere ar taki fel hyn o er reliable i hyn yn cael enodd rein i'r company- Felly, mae'r unig o'ch cyfnodd yma. Felly, nid oes yma, yw y cwmpo? Felly, yma, yw'n mynd i ddweud y MicroRNA Therapeutics yn gwneud unrhyw clywb gyda drwg ac mae'n ffyrwch arnau'r ffordd ar hyn o'r ffordd dros i'r cyfnodd o'r bydau. Fy oed. Dwi'n ddweud i ddweud i ddweud i ddweud i ddweud i ddyddai'r sloeg yn ymddangos. Ond yna'n gwneud yn ymddangos. Mae'r bynnag yw yw'r cyfnodd yma, pre-FDA approved so there is this area where sometimes it's either going to be a really big catalyst or and it could send the stock up or equally it could actually have a bad impact on the stock so this is pre-FDA many of their products are pre-FDA they aren't approved yet and and they're in that process they're in that pipeline of being approved but there is a potential that they will be approved and I think if you look into the company's history it's expertise and what they're trying to produce there you know there may be a potential of it actually happening so let's go into the so the investor so what is there so regulist therapeutics is a clinical stage by a pharmaceutical company focused on the discovery and development of innovative medicines targeting micro RNAs regulist has leveraged its only genul genulia side might pronounce that right I'm not too sure drug discovery and development expertise to to develop a well-balanced micro RNA therapeutics pipeline complemented by a rich intellectual property estate regulist is advancing program programs in re renal and hepactic diseases regulist maintains its corporate quarters in LA Jolla there we go so looking at if you look at this here it's involved in this industry and I think that actually there's a lot of catalysts for this area we'll go into this so first of all they've announced a new addition to the board of directors and if you actually look onto the website you'll notice that they do have a very credible leadership team and elite and board of directors right and and what I look for in particularly pharmaceutical companies but also companies in general is how effective is the leadership team because I think that can have a big impact on the success of a company based upon their leadership team so so looking into this so regulist therapeutics it talks about what who is there so it's an innovative medicines targeting micro RNAs and it announced alice s huang phd has been appointed to the company's board of directors concurrently with her appointed to the board to serve us in the compensation committee we are pleased to add Dr Wang at the regulist board we believe her extensive scientific background will be of benefit on helping direct the company's drug discovery and development programs it's currently senior faculty associate of biology and biological engineering that the california california institute of technology having joined call tech in June 9 July 1997 so she's essentially she's she's been involved here in a lot of areas and she's very this individual is very experienced and also well with that experience comes a lot of skills as well right that that can be added to the company but this is just another addition to their already growing what seems to be effective leadership team and it's in this area of biopharmaceutical biopharmaceutical company it's in this specific area where really an effective leadership team and particularly ones that are obviously expertise in science are really important right before we move on to any further information i was going to say turn on the notifications if you haven't already we do cover many different penny stocks of range of penny stocks and also normal stocks and growth stocks okay and many of the stocks we've talked about have run up we've got transcendrics we've had recently build a bear that's run up i'm going to talk about those at some point and many people laughed at me for investing in them they ain't laughing now because it's run up massively so there we go so moving into this you know there's a lot of stocks that we've talked about that has run up and it also had a comment recently on one of my other videos about cloud because i suggested it when it was at zero i think it was at 0.008 or you know just just a ridiculously lower level and it's and it dipped a little bit and then someone in the comments was mad at me and now today it's up a decent amount it's you know it's like this it's a penny stock right you know if you don't have the stomach for a penny stock don't invest in them that's what it was what i say um you've got to be and everybody who invests in penny stocks does understand that right i'm sure everybody here who invests in them is not first if if a penny stock goes down five ten percent we've we've got to have hands of steel right we can't just you know um be too bothered about that because you've got to look at the at the picture and your price targets and where you think the company's going to go and also your strategy medium long as well let's get back into this stockler because i'm rambling do apologise i'll get back into the information uh okay so i'll port syndrome it's it's involved in in actually helping in dealing with this so this is an inherent form of kidney disease okay and and they've got actually a product here that's in the work so they've got one of the products is called rg012 and it's transition development responsibilities for rg012 to its partner uh and so so in the terms of the treatment there it's in preclinical studies and has demonstrated pertinent inhibition of mir tweet 2121 in vitra and viva and it is an experimental model of uh this this area here so you see you'll notice that this is one that's in clinical studies at the minute it's preclinical studies okay it's particular drug the next one is actually a a common um monogenic disorder okay and this one here is being designed here and it's actually in also it's preclinical studies it's essentially they've got a range of products in their pipeline where it's not actually FDA approved yet but that's where the catalyst is you know and if you can get this penny stock cheap enough where it's the upside is more than the downside right i think there's got a potential to run up and clearly with the institutions buying and holding this stock they see some potential in this stock for the future in terms of the commercialization of their products but obviously before they can commercialize effectively they have to actually build towards that FDA approval um but but clearly big institutions think that that potentially could happen uh because they're holding this stock in massive amounts uh another person here you've got the actual president and chief executive officer here and i just thought it was just interesting to have a little bit of background research into who's actually taking this company forward um so he joined Regulus in january 2016 as chief operating officer principal finance officer he was appointed to president and chief executive officer in may 2017 his career includes roles at the executive vice president chief financial officer and chief business officer of um orexigen therapeutics managing director of amgen ventures and head of corporate development for amgen mr hagan has laid numerous strategic and financial transactions including the acquisitions of imunex and tullarac uh tullarac and the spin out of nirventron and relapsa as well as many other business development efforts totaling over 15 billion in value so this this individual is clearly very experienced in having in dealing with with with high value deals and acquisitions right and what's to say that this company can't actually acquire further companies and build up their portfolio that way and if he's got if this individual's got experience in that again that could be a catalyst as well in terms of potential acquisitions of other companies and that's that's one of the key points that i wanted to raise on that and you can also notice here is receiving mba you know is is you know very well educated in that sense and it's had a lot of experience in the bio pharmaceutical area not um uh in terms of in the bio pharmaceutical area but also as a business person as well and actually you know conducting deals and and and and acquisitions so it's a very very experienced individual now the current price is set at $1.50 okay and the thing is i didn't want to cover this stock when it already had a massive run up i was waiting for it to just kind of settle down a little bit because it had a massive run up and i'm like i was waiting so it's actually come down from you know its highs of $1.80 and it's come down to sort of $1.50 what i would say is to put this on your watch list and if you can get this anywhere around the sort of $1.20 $1.50 range i think that it might be worth holding in the hopes that you know they actually have these catalysts that i've been talking about in this video um and again this may be one of these holes that is more of a fairly patient hold but i do think that this could stop could explode in the medium to long term i really do think that and uh and that's what i think about this stock so anyways thank you for watching this video don't forget to leave the video a like subscribe to the channel if you're new and also we're trying to reach 10 000 subscribers as fast as we can so any help towards that is greatly appreciated so thanks to all the support on the channel i really do appreciate that and i'll see everybody in the next one